Balancing Innovation and Risk Management

Overview

A striking dichotomy exists between how biopharma companies and healthcare stakeholders perceive the value of biomedical innovation and novel drugs. Biopharma companies must work with key stakeholders to ensure that, upon approval, patients who would benefit from these novel treatments have timely access to them. Additionally, both innovation and risk management are important in commercializing these novel treatments. In this article, the RxC team profiles five key trends that are profoundly impacting the commercialization of novel treatments and their implications for biopharma companies.

1. Value-based healthcare is transforming the delivery of care

2. Consumerism in healthcare is a positive driving force

3. Personalized solutions are producing quality health outcomes

4. New technologies are enabling digital healthcare transformation

5. Supply chain networks are facilitating direct distribution models.

Download the White Paper